ABSTRACT
Signet ring cells (SRCs) are present in a variety of neoplasms from different anatomic sites. [1] [2] [3] SRCs are characterized by the accumulation of intracytoplasmic substances that indent and displace the nucleus to the periphery of the cell membrane, imparting a crescent-like appearance. The presence of SRCs in thyroid tumors has been reported in only a few individual case reports or very small series in the literature. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The importance of finding SRCs in thyroid fine-needle aspiration (FNA) specimens stems from its being a relatively rare finding in primary thyroid tumors and the overlapping morphology with metastatic carcinomas as well as parathyroid lesions, which can create a diagnostic challenge even on histopathology. The intracytoplasmic vacuoles have been reported to contain various Upon completion of this activity you will be able to:
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substances, including thyroglobulin (TG), mucin, lipid, or glycogen. 4, 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In some cases, defects in normal thyroid hormone production have been proposed as a cause of SRC formation. 7 To our knowledge, our cohort of seven cases is the largest FNA and surgical pathology series of primary thyroid neoplasms with SRCs that also explores the molecular changes associated with the presence of SRCs. To establish a more comprehensive understanding of this rare finding, we describe the cytologic, histologic, histochemical, and molecular features of all seven thyroid SRC cases, including one rare case of primary thyroid secretory carcinoma (SC).
Materials and Methods

Case Selection
The surgical pathology archives of the Massachusetts General Hospital and Brigham and Women's Hospital (Boston, MA) were retrospectively searched using the keywords thyroid, signet, and signet ring features between January 2000 and July 2014. Overall, 45 surgical pathology cases were initially identified; however, only seven cases were confirmed as having SRCs as well as a corresponding FNA. Human experiments were approved by the institutional review board at Partners Healthcare and Massachusetts General Hospital.
Pertinent clinical and pathologic information was collected from the medical records. Available FNA slides and corresponding histology slides were reviewed independently by two board-certified pathologists (A.M.O., W.C.F.) and one pathologist in training (N.A.F.). Cytology specimens included direct smears (air-dried Diff-Quik stained and alcohol-fixed Papanicolaou stained) as well as liquid based (ThinPrep [Hologic, Marlborough, MA] or SurePath [Becton Dickinson, Franklin Lakes, NJ]) preparations. Cytomorphologic features were evaluated based on cellularity, amount of colloid, presence of SRCs, amount of cytoplasm, nuclear shape, chromatin pattern, degree of nuclear pleomorphism, and presence of nuclear grooves. The proportion of the SRC component was estimated in the corresponding surgical resections and recorded as less than 10%, 10% to 30%, 30% to 50%, and more than 50%.
Ancillary Studies
All ancillary and molecular studies were performed on the corresponding histology specimens of our SRC cohort. The 4-µm-thick sections from paraffin-embedded tissue blocks containing the SRC tumor component were cut and stained histochemically using conventional methods with periodic acid-Schiff (with and without diastase; PAS and PAS/D), mucicarmine, and Alcian blue (AB). Immunohistochemical staining for TG (prediluted; Cell Marque, Rocklin, CA) was performed for all seven cases. In addition, for the case of SC, immunohistochemical evaluation using mammaglobin (prediluted; Ventana Medical Systems, Tucson, AZ), S100 (1:2,000; Dako, Santa Clara, CA), TTF1 (1:25; Diagnostic Biosystems, Pleasanton, CA), PAX8 (1:100; Proteintech, Chicago, IL), GCDFP-15 (1:1,000; Covance, Dedham, MA), Ki-67 (1:200; Dako), p53 (prediluted; Leica, Wetzler, Germany), BRAF (1:50; Spring Biosciences, Pleasanton, CA), chromogranin (1:1,000; Dako), and calcitonin (prediluted; Dako) was conducted by using a Ventana BenchMark XT autostainer (Ventana Medical Systems, Oro Valley, AZ). Positive and negative controls were used for all ancillary immunohistochemical studies.
For molecular analysis, the MGH SNapShot assay (Partners Healthcare, Boston, MA) using anchored multiplex polymerase chain reaction (PCR) technology (AMP) for single-nucleotide variant (SNV) and insertion/deletion (indel) detection in genomic DNA using next-generation sequencing (NGS) was performed. Genomic DNA was isolated from a formalin-fixed, paraffin-embedded tumor specimen after histologic review for tumor enrichment. The genomic DNA was sheared with the Covaris M220 instrument (Woburn, MA), followed by end repair, adenylation, and ligation with an adapter. A sequencing library targeting hotspots and exons in 39 genes was generated using two hemi-nested PCR reactions. Illumina (San Diego, CA) MiSeq 2 × 151 base paired-end sequencing results were aligned to the hg19 human genome reference using BWA-MEM. 18 MuTect and a laboratory-developed insertion/deletion analysis algorithm were used for SNV and indel variant detection, respectively. This assay has been validated to detect SNV and indel variants at 5% allelic frequency or higher in target regions with sufficient read coverage. Variants were reported with Human Genome Variation Society protein and DNA nomenclature, followed by the referenced Ensembl transcript ID. Molecular testing by AMP assay, based on PCR technology used for fusion transcript detection using targeted NGS, was also performed. Total nucleic acid was isolated from formalin-fixed, paraffin embedded tumor specimens, and the total nucleic acid was reverse transcribed with random hexamers, followed by second-strand synthesis to create double-stranded complementary DNA (cDNA). The double-stranded cDNA was end-repaired, adenylated, and ligated with a half-functional adapter. Two hemi-nested PCR reactions were applied to create a fully functional sequencing library that targeted ALK exons 19 to 22, ROS1 exons 31 to 37, RET exons 8 to 13, B2M exon 2, CTBP1 exon 6, and GAPDH exon 6. Illumina MiSeq 2 × 151 base pair paired-end sequencing results were aligned to the hg19 human genome reference using a combination of bwa and BLAT. A laboratory-developed algorithm was used for fusion transcript detection and annotation. The integrity of the input nucleic acid and the technical performance of the assay were assessed with control sequences from the B2M, CTBP1, and GAPDH targets.
Results
The study cohort consisted of six females and one male with a mean age of 58.3 years (range, 17-81 years). The mean tumor size was 2.6 cm (range, 0.9-4.5 cm) ❚Table 1❚.
Histopathologic Evaluation
Of the seven SRC cases, four were follicular adenomas (FAs). The SRC component of the FA cases comprised 30% to 50% in three and more than 50% in one case. The SRCs generally lined a part of the thyroid follicle, and rarely all the cells of an entire follicle exhibited SRC features. Cells were arranged in nests and trabeculae, separated by a capillary network and delicate fibrovascular septae. No extracellular mucin or dispersed SRCs were seen in any of the cases. All tumors showed a degree of degenerative change, such as stromal fibrosis, hemorrhage, or cystic change possibly secondary to FNA artifact.
Three of our cohort cases were originally classified as follicular variants of papillary thyroid carcinoma (PTC), but on review for this study, two cases were reclassified as noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTPs), and one case was reclassified as SC. The NIFTP cases met the detailed histologic criteria for NIFTP described in the recent study by Nikiforov et al. 19 They were encapsulated, follicular-patterned tumors showing PTC-like nuclear features and lacking evidence of invasion ❚Image 1❚. SRCs comprised 10% to 30% and less 
© American Society for Clinical Pathology
Farhat et al / Primary Benign and malignant thyroid neoPlasms With srCs than 10% of the two NIFTP cases, and their distribution was similar to the cohort cases of FA. The case of SC was an unencapsulated tumor measuring 3.2 cm. The carcinoma showed extensive involvement of the inked margins, extrathyroidal extension, and lymphovascular invasion. The tumor was composed of lobules of epithelial cells separated by a desmoplastic stroma. The cells formed cleft-like spaces with cribriform structures, papillae, and tubules. Individual tumor cells were enlarged with densely eosinophilic cytoplasm, and many SRCs contained prominent eosinophilic cytoplasmic vacuoles. The nuclear features of SC, especially the presence of enlarged oval, pale nuclei, resembled PTC. However, in contrast to classical PTC, the nuclei were evenly spaced (no overlapping), and nuclear contours were mostly smooth ❚Image 2❚. Nuclear grooves were rare, and intranuclear pseudoinclusions were not identified. Unlike the peripheral micronucleoli of PTC, the SC cells had prominent nucleoli. A component of chronic lymphocytic thyroiditis was present in the background. Two cervical lymph nodes showed metastatic SC at the time of the initial diagnosis.
Cytologic Evaluation
The initial cytologic diagnoses for our cohort of seven SRC cases were atypia/follicular lesion of undetermined significance in three cases, suspicious for follicular neoplasm in three cases, and suspicious for malignancy in one case. The cytologic findings are summarized in Table 1 .
The SRC cytomorphology showed variation between cases and also within a case. Six of seven cases were cellular, all cases had only scant colloid, and cytoplasm tended to be moderate ( Table 1) . Four of our seven SRC FNA cohort cases contained prominent SRCs (two FAs, one NIFTP, and one SC) ❚Image 3❚ and ❚Image 4❚. Among these FNA cases, two were acknowledged in the cytology reports as diagnostically challenging. In one of the FA cases, the presence of SRC in the FNA specimen raised the possibility of a parathyroid lesion.
The FNA case of SC was particularly unusual. The smears were hypercellular, with three-dimensional crowded groups as well as single dispersed cells in the background. The cells had moderate to abundant eosinophilic cytoplasm mimicking variants of PTC with oncocytic cytoplasm, such as the tall cell variant or the oncocytic variant of PTC. SRCs were easily identified; the cytoplasmic vacuolar contents were colorless or lightly eosinophilic ❚Image 5❚. Nuclei were enlarged and oval with even, pale chromatin reminiscent of the nuclear changes associated with PTC. However, in contrast to PTC, nuclear grooves were rare, and intranuclear pseudoinclusions were absent. In addition, nucleoli were prominent in most SC cells compared with the peripheral micronucleoli of PTC ❚Image 6❚. A minor subset of the SC cells was somewhat elongate to spindled, and the possibility of a medullary thyroid carcinoma (MTC) was originally considered. However, the chromatin pattern lacked the typical granular quality of MTC, and the cells of SC were more cohesive than MTC.
Histochemical and Immunohistochemical Features
Four of our cohort cases were positive for PAS, and only one case showed diastase resistance. AB was positive in two cases, and mucicarmine was positive in one case.
TG immunostaining in the SRC cytoplasm was present in all FA and NIFTP cases, but TG was focal and limited to rare cells in the case of SC (Table 1) . SC demonstrated positive immunohistochemical staining with mammaglobin, S-100, GCDFP-15, and p53, whereas BRAF, chromogranin, calcitonin, PAX8, and TTF1 were negative. The Ki-67 proliferation index was 10%. 
Molecular Analysis
Amplified multiplex PCR analysis (SNapShot) testing revealed several molecular abnormalities in the SRC cohort. A very prominent (>80% allele frequency) PTEN variant was found in one of the thyroid FA cases ❚Figure 1❚. Analysis of one of the NIFTP cases identified a low-frequency FGFR3 mutation (6% allele frequency) of uncertain significance. An important finding using the solid fusion molecular assay was the detection of an ETV6-NTRK3 gene fusion in the cohort case of SC. None of the FA and NIFTP cases showed common somatic mutations such as RAS or gene rearrangements ❚Table 2❚.
Discussion
Using a cohort of seven neoplastic thyroid cases with corresponding FNA, we describe the histologic, cytologic, histochemical, and molecular features of SRCs in these tumors. To our knowledge, our study is the largest series of SRCs to investigate these features, and it is the first SRC series containing NIFTP and a recently described SC of the thyroid. Our findings are concordant with the observations of others that a variety of thyroid neoplasms from FA to medullary thyroid carcinoma can exhibit SRCs. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 20 It is important to emphasize that the presence of SRCs should not be interpreted as evidence of a malignant thyroid neoplasm-on the contrary, six of our seven cases were benign or NIFTP. Our cohort of cases illustrates for the practicing cytologist and surgical pathologist some of the challenges and pitfalls associated with SRC-containing thyroid tumors.
Based on our cohort, the differential diagnosis of SRCs in thyroid specimens can include benign tumors, tumors of uncertain malignant potential, and less commonly carcinoma. Our cohort did not include any metastatic carcinomas with SRCs, but in the appropriate clinical setting, the presence of SRCs could suggest metastatic disease. Metastasis to the thyroid is relatively rare. [21] [22] [23] Renal cell carcinoma and breast and lung adenocarcinomas are the most common metastatic tumors to the thyroid gland, and features of SRCs have been described in those tumor types. [22] [23] [24] On the other hand, one of our FA cases had a cytologic differential diagnosis of a nonthyroidal tumor, a parathyroid adenoma. Parathyroid lesions can occasionally have abundant clear cytoplasm with cytoplasmic vacuoles. 25 In cases raising the differential diagnosis of a nonthyroid tumor such as a metastasis or a parathyroid lesion, ancillary immunocytochemical studies could be used to distinguish a primary thyroid neoplasm from a secondary neoplasm. As in our cohort, the presence of SRCs in a thyroid FNA is unlikely to cause diagnostic issues except in cases where it is a prominent component.
Two of our SRC cohort cases were originally classified as encapsulated follicular variants of PTC, but on histologic re-review, they fulfilled the recently described diagnostic criteria for NIFTP. 19 To our knowledge, these two cases are the first NIFTP cases described to contain SRCs. The most characteristic molecular changes identified in NIFTP are mutations in RAS; however, both NIFTP cases in our SRC cohort lacked RAS mutations. [26] [27] [28] The most unusual case in our cohort was a case of primary thyroid SC. SC is well recognized in the salivary gland; however, it has only recently been described in the thyroid gland. [29] [30] [31] [32] [33] In our series, the SC case was characterized by a very prominent component of SRCs. This finding demonstrates that although very rare, SC should be considered in the differential diagnosis of thyroid tumors with abundant SRCs. The FNA of this case was originally diagnosed as suspicious for PTC with SRCs, which is concordant with the findings of Reynolds et al. 32 The histochemical and immunohistochemical features of our case were similar to those described previously for SC. [30] [31] [32] [33] The immunohistochemical profile is significantly different from other primary thyroid tumors, being generally negative for TTF1 and TG, negative or weakly positive for PAX8, but strongly positive for mammaglobin. 30, 31 To date, there have been only eight cases of SC reported of primary thyroid origin, all showing ETV6-NTRK3 translocations. [30] [31] [32] [33] Our case of SC showed an ETV6-NTRK3 rearrangement as well, which made the classification of this tumor possible. This demonstrates the effectiveness of molecular testing for challenging thyroid tumors. With regard to clinical management of a patient with primary thyroid SC, the distinction from PTC is important since PTC can be treated with radioactive iodine, which would not be indicated for SC. In contrast, tyrosine kinase inhibitors represent a potential line of therapy for the management of primary thyroid SC. [30] [31] [32] The histochemical stains performed in our cohort of seven SRC cases revealed that most of the cytoplasmic content is due to the accumulation of TG. This is supported by several prior studies performed by other groups that also found and postulated that SRCs might be the result of an arrest in folliculogenesis or aborted TG exocytosis. 4, 5, 7, 8, 10, 11, [13] [14] [15] [16] In addition to TG, three of our cases also contained glycogen and one case contained mucin. Combined TG, PAS, PAS/D and/or AB positivity in the cytoplasm of thyroid SRCs have also been reported by other investigators and may result from polysaccharide complexes formed as a consequence of TG degradation, dual differentiation of follicular cells, or activation of genes related to mucin production during the neoplastic process. 8, 9, 14, 21 In contrast to the other cases in our cohort, the case of SC was predominantly negative for TG but positive for mucin.
The results of molecular studies from our cohort revealed unexpected findings. The most common molecular change identified in most NIFTP cases and in up to onethird of FAs is RAS gene mutations. [26] [27] [28] 34, 35 However, in our cohort of four FA and two NIFTP cases, none exhibited a RAS mutation. In contrast, one of our FA cases showed a PTEN mutation, and one of the NIFTP cases showed an FGFR3 mutation with a low (6%) allelic frequency. PTEN mutations can be associated with PTEN hamartoma tumor syndromes, including Cowden syndrome. 36 Interestingly, some of the studies investigating histomorphologic characteristics of thyroid lesions in Cowden syndrome have described clear cell features in their series, although SRCs have not been specifically reported. [36] [37] [38] To date, there are limited data on FGFR3 mutations in thyroid neoplasms, and the significance of this finding is unknown. 39, 40 Based on our SRC cohort, the histomorphologic presence of SRCs might suggest a molecular profile that does not include RAS mutations, although this needs additional studies with larger case series.
Conclusion
In conclusion, our cohort of SRC cases demonstrates that SRCs can be seen in a variety of benign and malignant thyroid tumors ranging from FA to NIFTP to SC. The presence of SRCs raises a differential diagnosis of nonthyroid disease such as a parathyroid neoplasm or metastasis, but in our experience, the tumors with SRCs were more often primary benign thyroid tumors. Finally, on the molecular level, the presence of SRCs was not associated in our series with RAS mutations.
